[1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
[2] |
Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3): 1020-1022.
|
[3] |
Crocetti L, Della Pina C, Cioni D, et al. Peri-intraprocedural imaging: US, CT, and MRI[J]. Abdom Imaging, 2011, 36(6): 648-660.
|
[4] |
Claudon M, Cosgrove D, Albrecht T, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)-update 2008[J]. Ultraschall Med, 2008, 29(1):28-44.
|
[5] |
Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours[J]. Cardiovasc Intervent Radiol, 2010, 33(1):11-17.
|
[6] |
Kim YS, Rhim H, Cho OK, et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors[J]. Eur J Radiol, 2006, 59(3):432-441.
|
[7] |
Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin[J]. AJR Am J Roentgenol, 2012, 188(2):480-488.
|
[8] |
Okuwaki Y, Nakazawa T, Shibuya A, et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns[J]. J Gastroenterol, 2008, 43(1):71-78.
|
[9] |
Abi-Jaoudeh N, Kruecker J, Kadoury S, et al. Multimodality image fusion-guided procedures: technique, accuracy, and applications[J]. Cardiovasc Intervent Radiol, 2012, 35(5): 986-998.
|
[10] |
Lee JY, Choi BI, Chung YE, et al.Clinical value of CT/MR-US fusion imaging for radiofrequency ablation of hepatic nodules[J]. Eur J Radiol, 2012, 81(9):2281-2289.
|
[11] |
Zhong-Zhen S, Kai L, Rong-Qin Z, et al. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma[J]. Ultraschall Med, 2012, 33(7): E250-255.
|
[12] |
中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011, 27(11): 1141-1159.
|
[13] |
Crocetti L, Lencioni R, Debeni S, et al. Targeting liver lesions for radiofrequency ablation: an experimental feasibility study using a CT-US fusion imaging system[J]. Invest Radiol, 2008, 43(1):33-39.
|
[14] |
Ewertsen C, Henriksen BM, Torp-Pedersen S, et al. Characterization by biopsy or CEUS of liver lesions guided by image fusion between ultrasonography and CT, PET/CT or MRI[J]. Ultraschall Med, 2011, 32(2):191-197.
|
[15] |
Mauri G, Cova L, De Beni S, et al. Real-time US-CT/MRI image fusion for guidance of thermal ablation of liver tumors undetectable with US: results in 295 cases[J]. Cardiovasc Intervent Radiol, 2015, 38(1): 143-151.
|
[16] |
李凯,曾庆劲,郑荣琴,等.导航引导和导航超声造影辅助消融超声显示困难肝癌[J].中山大学学报: 医学科学版,2012, 33(4): 549-552.
|
[17] |
袁树芳,李凯,郑荣琴,等. 超声-CT/MR融合成像分析肝局灶性病变常规超声显示困难的原因[J]. 中华超声影像学杂志,2014, 23(3): 235-238.
|
[18] |
Tomonari A, Tsuji K, Yamazaki H, et al. Feasibility of fused imaging for the evaluation of radiofrequency ablative margin for hepatocellular carcinoma[J]. Hepatol Res, 2013, 43(7):728-734.
|
[19] |
鞠金秀,李凯,郑荣琴,等.术中CT/MR-超声造影融合成像与常规超声造影评估肝癌消融疗效的比较[J].中华超声影像学杂志,2015, 24(6): 508-511.
|
[20] |
Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review[J]. Hepatol Res, 2015, 45(1):59-74.
|